These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 22128084)

  • 21. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
    Poddubnyy D; Hermann KG; Callhoff J; Listing J; Sieper J
    Ann Rheum Dis; 2014 May; 73(5):817-23. PubMed ID: 24389297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.
    Horneff G; Fitter S; Foeldvari I; Minden K; Kuemmerle-Deschner J; Tzaribacev N; Thon A; Borte M; Ganser G; Trauzeddel R; Huppertz HI
    Arthritis Res Ther; 2012 Oct; 14(5):R230. PubMed ID: 23095307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study.
    Haroon M; Ahmad M; Baig MN; Mason O; Rice J; FitzGerald O
    Arthritis Res Ther; 2018 Apr; 20(1):73. PubMed ID: 29665824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion.
    Rudwaleit M; Olivieri I; Boki KA; Griep EN; Järvinen P; Wong RL; Kron M; Kary S; Kupper H
    Rheumatology (Oxford); 2009 May; 48(5):551-7. PubMed ID: 19254918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X; Braun J; Deodhar A; Poddubnyy D; Kivitz A; Tahir H; Van den Bosch F; Delicha EM; Talloczy Z; Fierlinger A
    RMD Open; 2019; 5(2):e001005. PubMed ID: 31565244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized, placebo controlled and double-blind trials of efficacy and safety of adalimumab for treating ankylosing spondylitis: a meta-analysis.
    Wang H; Zuo D; Sun M; Hua Y; Cai Z
    Int J Rheum Dis; 2014 Feb; 17(2):142-8. PubMed ID: 24506823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
    Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC; Baeten D; Sieper J; Deodhar A; Bhosekar V; Martin R; Porter B
    Int J Rheum Dis; 2017 May; 20(5):589-596. PubMed ID: 28544533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial.
    van der Heijde D; Braun J; Dougados M; Sieper J; Pedersen R; Szumski A; Koenig AS
    Rheumatology (Oxford); 2012 Oct; 51(10):1894-905. PubMed ID: 22772319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upadacitinib for axial spondyloarthritis: a meta-analysis of efficacy and safety.
    Tang H; Liu X; Zhao J; Tang Z; Zheng Z; Bai W
    Clin Rheumatol; 2024 Aug; 43(8):2391-2402. PubMed ID: 38874670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
    Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
    Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years.
    Baraliakos X; Haibel H; Fritz C; Listing J; Heldmann F; Braun J; Sieper J
    Arthritis Res Ther; 2013; 15(3):R67. PubMed ID: 23786760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
    Sieper J; Landewé R; Rudwaleit M; van der Heijde D; Dougados M; Mease PJ; Braun J; Deodhar A; Kivitz A; Walsh J; Hoepken B; Nurminen T; Maksymowych WP
    Arthritis Rheumatol; 2015 Mar; 67(3):668-77. PubMed ID: 25470228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.
    van der Heijde DM; Revicki DA; Gooch KL; Wong RL; Kupper H; Harnam N; Thompson C; Sieper J;
    Arthritis Res Ther; 2009; 11(4):R124. PubMed ID: 19686597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
    van der Heijde D; Gensler LS; Deodhar A; Baraliakos X; Poddubnyy D; Kivitz A; Farmer MK; Baeten D; Goldammer N; Coarse J; Oortgiesen M; Dougados M
    Ann Rheum Dis; 2020 May; 79(5):595-604. PubMed ID: 32253184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
    van der Heijde D; Breban M; Halter D; DiVittorio G; Bratt J; Cantini F; Kary S; Pangan AL; Kupper H; Rathmann SS; Sieper J; Mease PJ
    Rheumatology (Oxford); 2015 Jul; 54(7):1210-9. PubMed ID: 25541333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension.
    Deodhar A; van der Heijde D; Sieper J; Van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Ostor A; Combe B; Sui Y; Chu AD; Song IH
    Arthritis Rheumatol; 2022 Jan; 74(1):70-80. PubMed ID: 34196498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).
    Revicki DA; Luo MP; Wordsworth P; Wong RL; Chen N; Davis JC;
    J Rheumatol; 2008 Jul; 35(7):1346-53. PubMed ID: 18484692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.